Millions of people now take GLP-1 receptor agonist drugs such as semaglutide and liraglutide for diabetes and weight loss. A ...

Generic medications are approved by the FDA because they have the same safety and effectiveness profiles as the name-brand or ...

In a comparison of injectable GLP-1 receptor agonists, semaglutide (Wegovy) appeared to edge out liraglutide (Saxenda) when it came to weight loss, according to the phase IIIb STEP 8 study. In a ...

Adults living with obesity and frequent migraines saw their monthly headache days drop by nearly half after adding the weight-loss drug liraglutide to their existing treatment, according to a small ...

The obesity medication liraglutide is safe and effective in children aged 6 to <12 years, new research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD ...

Liraglutide and tirzepatide are two common glucagon-like peptide-1 (GLP-1) receptor agonist medications. With so many different GLP-1 medications on the market, as well as approved uses, forms and ...

New study reveals semaglutide outperforms liraglutide in weight loss for obesity, highlighting key factors that contribute to significant weight reduction in patients. Study: One-Year Weight Reduction ...

People with severe obesity who exercise regularly have healthier blood vessels and lower inflammation than those who rely on ...

The FDA's approval of the glucagon-like peptide receptor agonist marks the first non-insulin drug approved for youth with type 2 diabetes since the approval of metformin for pediatric use in 2000.

Share on Pinterest Can a GLP-1 drug help protect against cognitive decline? Early trials say ‘yes.’ Image credit: Halfpoint Images/Getty Images. Over the last year, the use of and interest in glucagon ...

KELOWNA, BC / ACCESS Newswire / February 20, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it ...

A network meta-analysis of nine randomized controlled trials found that once-weekly semaglutide showed the largest estimated ...